Author Of 1 Presentation

Clinical Outcome Measures Poster Presentation

P0127 - Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria (ID 252)

Presentation Number
Presentation Topic
Clinical Outcome Measures



Studies matching the clinical efficacy between fingolimod (FTY), dimethylfumarate (DMF) and teriflunomide (TERI) provided conflicting results. These discrepancies ask for further investigations to confirm or rebut the published findings, especially by real-life experiences.


To compare the efficacies, frequencies and reasons for treatment interruption of FTY, DMF or TERI in a nationwide observational cohort.


Twocohorts of patients with relapsing-remitting multiple sclerosis (RRMS) having started treatment with FTY, DMF or TERI documented in the Austrian MS Treatment Registry (AMSTR) since 2014 and either staying on therapy for at least 24 months (24m cohort) or with at least one follow-up visit after start of treatment (total cohort). The 24m cohort included 629 RRMS patients: 295 in the FTY, 227 in the DMF and 107 in the TERI group. We used multinomial propensity scores for inverse probability weighting in generalized linear and Cox proportional hazards models to correct for the bias of this non-randomised registry study.


Estimated mean annualized relapse rates (ARR) over 24 months were 0.13 for FTY, 0.09 for DMF and 0.11 for TERI treatment. For TERI in comparison with DMF, we observed higher probability for treatment interruption (p=0.023) and reduced sustained EDSS regression for 12 (p=0.016) and 24 weeks (p=0.031) and, for the comparison of DMF versus FTY, a reduced sustained EDSS progression for 12 weeks (p=0.02).


Relapse rates with treatment with FTY, DMF and TERI were similar. Patients treated with DMF showed less sustained disability progression for 12 weeks than FTY treated patients. However, FTY and DMF treatment was associated with more likely EDSS regression for 12 and 24 weeks and a lowerprobability for treatment interruptionas compared to TERI treated patients.